ADMA Biologics Inc ADMA

9.38 (0.14) (1.47%) as of 25 Sep
Market cap
$2.1B
P/E
13.0×
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue
510.17 426.45 258.22 154.08 80.94 42.22 29.35 16.99 22.76 10.66
Revenue Growth
19.63% 65.15% 67.59% 90.36% 91.72% 43.85% 72.79% (25.37%) 113.49% 48.53%
Cost of Revenue
217.41 206.90 169.27 118.82 79.77 61.29 39.50 42.19 29.16 6.36
Gross Profit
292.77 219.55 88.94 35.27 1.17 (19.07) (10.16) (25.21) (6.40) 4.30
R&D Expenses
4.76 1.81 3.30 3.61 3.65 5.91 2.34 3.93 5.57 7.69
SG&A Expenses
91.58 74.12 59.02 52.46 42.90 35.05 25.91 22.50 18.75 8.49
Operating Income
191.44 138.98 21.63 (39.36) (58.37) (64.91) (41.42) (60.29) (39.31) (17.33)
Non-operating Income/Expense
(8.79) (13.27) (49.87) (26.54) (13.27) (10.83) (6.85) (5.45) (4.45) (2.18)
Non-operating Interest Expenses
7.11 13.93 25.03 19.28 13.06 11.99 8.99 5.52 3.29 2.24
EBT
182.66 125.71 (28.24) (65.90) (71.65) (75.75) (48.28) (65.74) (43.76) (19.52)
Income Tax Provision
35.73 (71.96) 0.00 (0.21) (0.24) — — — — —
Income after Tax
146.93 197.67 (28.24) (65.90) (71.65) (75.75) (48.28) (65.74) (43.76) (19.52)
Dividends (Preferred)
0.00 — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Income Common
146.93 197.67 (28.24) (65.90) (71.65) (75.75) (48.28) (65.74) (43.76) (19.52)
EPS (Basic)
0.62 0.85 (0.13) (0.33) (0.51) (0.88) (0.89) (1.45) (1.91) (1.61)
EPS (Diluted)
0.60 0.81 (0.13) (0.33) (0.51) (0.88) (0.89) (1.45) (1.91) (1.61)
Shares (Basic, Weighted)
238.30 233.08 223.98 197.88 139.58 86.15 54.35 45.19 22.90 12.15
Shares (Diluted, Weighted)
244.91 243.34 223.98 197.88 139.58 86.15 54.35 45.19 22.90 12.15
Gross Margin
57.39% 51.48% 34.44% 22.89% 1.45% (45.17%) (34.60%) (148.42%) (28.14%) 40.34%
EBIT Margin
37.53% 32.59% 8.38% (25.55%) (72.12%) (153.75%) (141.14%) (354.95%) (172.71%) (162.56%)
EBT margin
35.80% 29.48% (10.94%) (42.77%) (88.52%) (179.41%) (164.50%) (387.06%) (192.26%) (183.05%)
Net Profit Margin
28.80% 46.35% (10.94%) (42.77%) (88.52%) (179.41%) (164.50%) (387.06%) (192.26%) (183.05%)
Free Cash Flow Margin
5.39% 25.82% 1.48% (47.65%) (155.52%) (271.74%) (272.60%) (381.36%) (175.51%) (172.05%)
EBITDA
200.11 147.84 32.42 (29.99) (51.12) (59.33) (37.13) (55.88) (35.98) (16.33)
EBIT
191.44 138.98 21.63 (39.36) (58.37) (64.91) (41.42) (60.29) (39.31) (17.33)
Income from Continuous Operations
146.93 197.67 (28.24) (65.90) (71.65) (75.75) (48.28) (65.74) (43.76) (19.52)
Consolidated Net Income/Loss
146.93 197.67 (28.24) (65.90) (71.65) (75.75) (48.28) (65.74) (43.76) (19.52)
EPS (Basic, from Continuous Ops)
0.62 0.85 (0.13) (0.33) (0.51) (0.88) (0.89) (1.45) (1.91) (1.61)
EPS (Basic, Consolidated)
0.62 0.85 (0.13) (0.33) (0.51) (0.88) (0.89) (1.45) (1.91) (1.61)
EPS (Diluted, from Cont. Ops)
0.60 0.81 (0.13) (0.33) (0.51) (0.88) (0.89) (1.45) (1.91) (1.61)
Shares (Diluted, Average)
244.91 243.34 223.98 197.88 139.58 86.15 54.35 45.19 22.90 12.15
EPS (Diluted, Consolidated)
0.60 0.81 (0.13) (0.33) (0.51) (0.88) (0.89) (1.45) (1.91) (1.61)
EBITDA Margin
39.22% 34.67% 12.55% (19.47%) (63.16%) (140.53%) (126.51%) (329.00%) (158.08%) (153.14%)
Operating Cash Flow Margin
9.88% 27.83% 3.41% (38.62%) (138.82%) (241.60%) (259.61%) (369.02%) (163.76%) (171.36%)

Fold the line items

In millions of $ except per-share values · columns are period end dates